First Trust NYSE Arca Biotechnology Index Fund (FBT)
| Assets | $1.27B |
| NAV | $131.11 |
| Expense Ratio | 0.55% |
| PE Ratio | 15.11 |
| Shares Out | 9.70M |
| Dividend (ttm) | $2.21 |
| Dividend Yield | 1.72% |
| Ex-Dividend Date | Dec 30, 2021 |
| 1-Year Return | -25.63% |
| Volume | 27,360 |
| Open | 130.44 |
| Previous Close | 131.06 |
| Day's Range | 128.51 - 131.95 |
| 52-Week Low | 121.68 |
| 52-Week High | 172.92 |
| Beta | 0.85 |
| Holdings | 31 |
| Inception Date | Jun 19, 2006 |
About FBT
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of small, mid and large capitalization companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.
Top 10 Holdings
40.61% of assets| Name | Symbol | Weight |
|---|---|---|
| Alnylam Pharmaceuticals | ALNY | 4.91% |
| Agios Pharmaceuticals | AGIO | 4.62% |
| Sarepta Therapeutics | SRPT | 4.61% |
| Regeneron Pharmaceuticals | REGN | 4.08% |
| Ionis Pharmaceuticals | IONS | 3.91% |
| ACADIA Pharmaceuticals | ACAD | 3.90% |
| Neurocrine Biosciences | NBIX | 3.87% |
| Illumina | ILMN | 3.58% |
| Gilead Sciences | GILD | 3.57% |
| FibroGen | FGEN | 3.55% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 30, 2021 | $2.2136 | Jan 10, 2022 |
| Sep 23, 2015 | $0.0197 | Sep 30, 2015 |
| Jun 24, 2015 | $0.0649 | Jun 30, 2015 |
| Mar 25, 2015 | $0.0476 | Mar 31, 2015 |
| Dec 23, 2014 | $0.0524 | Dec 31, 2014 |
News
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
Sector ETF report for FBT
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
Smart Beta ETF report for FBT
Healthcare Emerges as Best Sector of Last Week: 5 Top ETFs
Wall Street was downbeat last week with all indexes in the red. Still, Healthcare sector emerged as a key winner last week.
Can Biotech ETFs Gain From Positive Booster Update?
In an effort to combat the coronavirus outbreak and accelerate the distribution process of extra doses in the United States, the FDA has approved the vaccine booster shots.
Biotech ETFs to Benefit From Latest Booster Update
The U.S. government's plans to make COVID-19 vaccine booster shots available from next month will likely increase the profits of vaccine makers.
Delta Variant Surge Brings Biotech ETFs in Focus
The biotech sector seems like a lucrative investment space as the delta variant of coronavirus continues to spread.
Will Biotech ETFs Benefit from Biogen's New Alzheimer's Drug?
Biotech investors may have reason to celebrate this week, as the FDA approved Biogen's Alzheimer's disease drug Aducanumab on Monday, ushering in the first medication to be allowed by U.S. regulators to...
Biotech ETFs to Suffer as US Backs IP Waiver for COVID-19 Vaccines
The Biden administration recently informed about supporting the waiver of intellectual property protections for COVID-19 vaccines that has been proposed by South Africa and India.
Top COVID-19 Vaccine Stories of March Put Biotech ETFs in Focus
Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.
ETFs to Tap AstraZeneca Mega-Deal to Buy Alexion
AstraZeneca has agreed to buy rare-disease specialist Alexion Pharmaceuticals for $39 billion. The deal would represent the biggest transaction in pharmaceuticals since 2019.
3 ETFs For AstraZeneca's $39B Alexion Pharmaceuticals Takeover
The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a $39-billion takeover of Alexion ...
ETF Sectors to Bet on Positive Vaccine News
The introduction of the coronavirus vaccine is expected to help in the economic recovery, especially for sectors which have taken a hit from the social-distancing and lockdown measures.
Can't Get Enough Biotech Exposure in Your Portfolio?
As coronavirus cases start to tick upwards once more, the race to create a vaccine will only intensify, boding well for the biotechnology sector. ETF investors may want to keep an eye on biotech funds, ...
Biotech ETFs at multi-week highs, extending winning streak
Biotechnology exchange-traded funds outperformed Tuesday as investors focused on next-generation solutions to the coronavirus and more. The ARK Genomic Revolution ETF was up 2.2% in the early afternoon,...
Biotech ETFs at two-week highs on upbeat vaccine news
Biotech exchange-traded funds got a bounce Friday from bullish news on coronavirus treatments. The ALPS Medical Breakthroughs ETF , the ARK Genomic Revolution ETF , and the First Trust NYSE Arca Biotech...
7 Biotech Stocks To Buy For Profit From The Vaccine Crunch
As the race to develop a vaccine continues, these biotech stocks could be high risk, high return propositions. The post 7 Biotech Stocks To Buy For Profit From The Vaccine Crunch appeared first on Inves...
Biotech ETFs in Focus as the COVID-19 Vaccine Race Intensifies
Johnson & Johnson's entry into the late-stage trials has increased optimism in the coronavirus vaccine development.
3 Healthcare ETFs to Buy for Health and Safety
Not all healthcare ETFs are the same and as this group of three proves, that can be a positive for savvy investors. The post 3 Healthcare ETFs to Buy for Health and Safety appeared first on InvestorPlace.
Encouraging Election Year History for this Biotech ETF
Healthcare is one of the most politically sensitive sectors and that sensitivity is on full display in recent weeks with biotechnology ETFs, including the First Trust NYSE Arca Biotechnology Index Fund ...